HeartBeam (NASDAQ: BEAT) announced its first-quarter 2026 operational and financial results, highlighting the launch of initial commercial partnerships in key U.S. markets and progress in its heart attack detection and ambulatory ECG patch initiatives. The company reported a net loss of $4.7 million for the quarter, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform.
The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software clearance in December 2025, is designed to enable cable-free collection of ECG signals from three non-coplanar directions. This platform allows physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management. HeartBeam holds over 20 issued patents related to its technology.
In April 2026, the company completed a public offering that raised $11.5 million in gross proceeds, providing additional capital to support commercial expansion. The company's initial commercial partnerships are focused on bringing its platform to patients in key U.S. markets, with the goal of improving access to cardiac monitoring and early detection of heart attacks.
HeartBeam's technology aims to address critical gaps in cardiac care by enabling portable, easy-to-use devices that can deliver actionable heart intelligence wherever the patient is. The company believes its platform can help reduce healthcare costs and improve outcomes by allowing earlier intervention and more efficient use of healthcare resources.
The full press release with detailed financial information is available at https://ibn.fm/guMCF. For more information about HeartBeam and its technology, including cleared indications for use, visit https://www.heartbeam.com/indications.
Forward-looking statements in this announcement involve risks and uncertainties, as detailed in the company's filings with the SEC. HeartBeam undertakes no duty to update these statements unless required by law.
